Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Authors:
- Renata VarnaitėRVRenata Varnaitė
- Marina GarcíaMGMarina García
- Hedvig GlansHGHedvig Glans
- Kimia T. MalekiKMKimia T. Maleki
- John Tyler SandbergJSJohn Tyler Sandberg
- Janne TynellJTJanne Tynell
- Wanda ChristWCWanda Christ
- Nina LagerqvistNLNina Lagerqvist
- Hilmir AsgeirssonHAHilmir Asgeirsson
- Hans-Gustaf LjunggrenHLHans-Gustaf Ljunggren
- Gustaf AhlénGAGustaf Ahlén
- Lars FrelinLFLars Frelin
Preprint
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a global pandemic. Pathogen-specific antibodies are typically a major predictor of protective immunity, yet B cell and antibody responses during COVID-19 are not fully understood. Here, we analyzed antibody-secreting cell (ASC) and antibody responses in twenty hospitalized COVID-19 patients. The patients exhibited typical symptoms of COVID-19, and presented with reduced lymphocyte numbers and increased T cell and B cell activation. Importantly, we detected an expansion of SARS-CoV-2 nucleocapsid protein-specific ASCs in all twenty COVID-19 patients using a multicolor FluoroSpot assay. Out of the 20 patients, 16 had developed SARS-CoV-2-neutralizing antibodies by the time of inclusion in the study. SARS-CoV-2-specific IgA, IgG and IgM antibody levels positively correlated with SARS-CoV-2-neutralizing antibody titers, suggesting that SARS-CoV-2-specific antibody levels may reflect the titers of neutralizing antibodies in COVID-19 patients during the acute phase of infection. Lastly, we showed that interleukin 6 (IL-6) and C-reactive protein (CRP) concentrations were higher in serum of patients who were hospitalized for longer, supporting the recent observations that IL-6 and CRP could be used to predict COVID-19 severity. Altogether, this study constitutes a detailed description of clinical and immunological parameters in twenty COVID-19 patients, with a focus on B cell and antibody responses, and provides tools to study immune responses to SARS-CoV-2 infection and vaccination.Keywords
All Related Versions
- Published version: The Journal of Immunology, 205 (9), 2437.
This publication has 24 references indexed in Scilit:
- The generation of antibody-secreting plasma cellsNature Reviews Immunology, 2015
- Virus-Specific Antibody Secreting Cell, Memory B-cell, and Sero-Antibody Responses in the Human Influenza Challenge ModelThe Journal of Infectious Diseases, 2014
- Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in HumansJournal of Virology, 2012
- Quorum-Sensing in CD4+ T Cell Homeostasis: A Hypothesis and a ModelFrontiers in Immunology, 2012
- Circulating Human Antibody-Secreting Cells during Vaccinations and Respiratory Viral Infections Are Characterized by High Specificity and Lack of Bystander EffectThe Journal of Immunology, 2011
- Circulating Antibody‐Secreting Cells during Acute Respiratory Syncytial Virus Infection in AdultsThe Journal of Infectious Diseases, 2010
- Elucidation of seventeen human peripheral blood B‐cell subsets and quantification of the tetanus response using a density‐based method for the automated identification of cell populations in multidimensional flow cytometry dataCytometry Part B: Clinical Cytometry, 2010
- Blood-borne human plasma cells in steady state are derived from mucosal immune responsesBlood, 2009
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008
- Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT systemJournal of Immunological Methods, 2004